Victor L. Roberts, MD, oversees all aspects of patient care and office operations as a primary provider and head administrator of Endocrine Associates of Florida in Lake Mary. Victor L. Roberts, MD, also has a history of publication in peer-reviewed journals, including Clinical Therapeutics and Endocrine Practice.
In 2009, he joined with five colleagues in publishing “Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea” in Current Medical Research and Opinion. This frequently cited article established biphasic insulin aspart 70/30 (BIAsp 30) as an attractive alternative to exenatide. These two medications are prescription treatments for type 2 diabetes. The article ultimately concludes that type 2 diabetes patients who have been unable to control their condition with a combination of metformin and sulfonylurea treatment are more likely to hit glycemic goals under BIAsp 30 treatment. Although they might experience minor hypoglycemic events and weight gain, BIAsp 30 patients report fewer and less severe gastrointestinal side-effects than exenatide patients do.
0 Comments
Leave a Reply. |
AuthorDr. Victor Roberts Archives
September 2021
CategoriesAll Community Outreach Covid-19 Cushing’s Syndrome Diabetes Health Hormonal Causes Hypothyroidism Urination Victor L Roberts MD |